Concepedia

Wayne Greaves

WG

41

Publications

3.1K

Citations

26

H-Index

1980

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Harvard University

Brigham and Women's Hospital

Johns Hopkins University

Cornell University

Wayne Greaves is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, infection control, and hiv.

Top concepts

Publications per year

1980–2021

41

Publications

41

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

David Roth, David R. Nelson, Annette Bruchfeld et al. · The Lancet · 2015 · 663 citations · Full text

, , +10

Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV‐1–Infected, Treatment‐Experienced Patients: AIDS Clinical Trials Group 5211

Roy M. Gulick, Zhaohui Su, Charles Flexner et al. · The Journal of Infectious Diseases · 2007 · 239 citations · Full text

Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo

Athe Tsibris, Bette Korber, Ramy Arnaout et al. · PLoS ONE · 2009 · 224 citations · Full text

HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211

Timothy Wilkin, Zhaohui Su, Daniel R. Kuritzkes et al. · Clinical Infectious Diseases · 2007 · 182 citations · Full text

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial

Mark Sulkowski, Stanislas Pol, Josep Mallolas et al. · The Lancet Infectious Diseases · 2013 · 180 citations

, , +9

Rows per page

1–5 of 41